Default company panoramic image
Logo

CalAsia Pharmaceuticals, Inc

Crossing Barriers in Drug Discovery TM

  • Stage Product In Development
  • Industry Biotechnology
  • Location San Diego, CA, USA
  • Currency USD
  • Founded October 2009
  • Employees 4
  • Website calasiapharma.com

Company Summary

1. Proprietary platform for discovering ‘constraint’ drugs, directed specifically to modulate the activity of chaperone proteins and to cross the blood-brain and ocular barriers. 2. Early stage pipeline extending to pre-clinical stage. 3. Team experienced in discovery of approved drug products, and with globally-recognized strengths in target indications. 4. Predominantly non-dilutive funding to date.

Team

  • Default avatar
    Allan Earl Rubenstein
    Chariman of Board

    Allan E. Rubenstein, MD, Chairman, a world leader in NF, founded and was the CEO of NexGenix Pharma, a HSP90 inhibitor based company. Currently is vice-chairman and lead director of Cooper Companies (NYSE: COO). Founded the Children’s Tumor Foundation and established the first interdisciplinary NF clinic in the world. Worked with DoD to setup the NF research grant funding program. He has been recognized in Who's Who in the East and Who's Who in

  • Default avatar
    Jeffrey W Stebbins
    Head of Biology and Pharmacology

    Jeffrey Stebbins, PhD, Head Biology/Pharmacology, led the team that discovered a clinical candidate for the treatment of obesity and Bayer, BAY 74-4113.

  • Default avatar
    Sridhar Govinda Prasad
    Co-founder and Vice President of Research

    Sridhar Prasad, PhD, is the VP of Research, led crystallography teams for multiple drug discovery programs, including Nesina, a Type 2 diabetes drug, recently approved by FDA and MK-4965, a Merck second generation HIV-1 AIDS drug currently in clinical trials.

  • Default avatar
    Prof. John M. Newsam
    Strategic Investment and Business Advisor

    A widely-published and decorated materials scientist with extensive entrepreneurial experience, through multiple exits, as a company founder, CSO, SVP of Business Development and CEO.

  • Default avatar
    Krishna Sharma
    Scientific Advisory Board

    Professor of Ophthalmology, Joint Professor of Biochemistry. Univ. of Missouri, Columbia, MO.
    http://biochem.missouri.edu/faculty/faculty-members/sharmak/index.php

  • Default avatar
    Marco Giovannini, MD, PhD
    Clinical Advisor

    Marco Giovannini, M.D., Ph.D., is the head of the Department of Neural Tumor Research at House Research Institute, Los Angles, CA. A native of Italy, Dr. Giovannini most recently served as Director of the Functional Genomics and Tumor Research Laboratory at the University of Paris VII in France and as chief scientific officer at NexGenix Pharmaceuticals in Burlingame, California. Marco Giovannini earned his medical degree at the University of Bol

  • Default avatar
    Gullapalli N. Rao, MD
    Clinical Advisor

    Distinguished Chair of Eye Health
    Chair, Hyderabad Eye Institute
    Founder, L V Prasad Eye Institute

    Gullapalli N Rao returned to India in 1986 to establish L V Prasad Eye Institute, after a successful career in the United States as an academic ophthalmologist. Dr Rao received his basic medical education in Guntur, Andhra Pradesh, and completed his postgraduate training in ophthalmology at the All India Institute for Medical Sciences, New Delh

Previous Investors

  • Default avatar
    National Institutes of Health - Grant Funding
    Unconfirmed
    Default avatar
    Michael J. Fox Foundation for Parkinson's Research - Grant Funding
    Unconfirmed